CHU de Quebec-Universite Laval

11 marketed · 3 in Phase 3

Quick facts

Marketed products

Phase 3 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about CHU de Quebec-Universite Laval

What are CHU de Quebec-Universite Laval's marketed drugs?

Top marketed products include 4CMenb, Acetylsalicylic Acid 80 mg, Anti-TNFα continued perioperatively, Anti-TNF suspended perioperatively, Brand-name latanoprost, Generic latanoprost.

What is CHU de Quebec-Universite Laval's pipeline?

CHU de Quebec-Universite Laval has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Bifilact®, Enzalutamide capsule, pr Sandoz Tamsulosin.

Related